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Abstract
Stimulation of TLR7/9 by their respective ligands leads to the activation of IkB kinase a (IKKa) and Interferon Regulatory
Factor 1 (IRF-1) and results in interferon (IFN)-b production in conventional dendritic cells (cDC). However, which other
signaling molecules are involved in IKKa and IRF-1 activation during TLR7/9 signaling pathway are not known. We and
others have shown that Bruton’s Tyrosine Kinase (BTK) played a part in TLR9-mediated cytokine production in B cells and
macrophages. However, it is unclear if BTK participates in TLR7/9-induced IFN-b production in cDC. In this study, we show
that BTK is required for IFN-b synthesis in cDC upon TLR7/9 stimulation and that stimulated BTK-deficient cDC are defective
in the induction of IKKa/b phosphorylation and IRF-1 activation. In addition, we demonstrate that Protein Kinase C m (PKCm)
is also required for TLR7/9-induced IRF-1 activation and IFN-b upregulation in cDC and acts downstream of BTK. Taken
together, we have uncovered two new molecules, BTK and PKCm, that are involved in TLR7/9-triggered IFN-b production in
cDC.
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Introduction
Conventional dendritic cells (cDC) and plasmacytoid dendritic
cells (pDC) recognize single-stranded (ss) RNA and unmethylated
CpG DNA via Toll-like receptors (TLR) 7 and 9, respectively, to
initiate innate immune responses against viruses and bacteria
[1,2,3,4]. TLR7 and TLR9 are endosome-bound, leucine-rich-
repeat containing type I transmembrane glycoproteins and they
signal via the adaptor MyD88 to induce the production of
proinflammatory cytokines and type I interferons (IFN) [2,5]. The
secretion of proinflammatory cytokines is dependent on the
activation of the transcription factor nuclear factor kB (NF-kB)
while the synthesis of type I IFN is dependent on the combined
activation of NF-kB and IFN regulatory factors (IRF) [6,7]. The
IRF family of transcription factors comprises nine members (IRF-
1–9), and which IRF is activated depends on the specific cell type
involved. For instance, pDC rapidly produce high amounts of
IFN-a through the induction of the transcription factor IRF-7
[8,9,10], whereas IRF-1 is activated and translocated to the
nucleus to induce IFN-b systhesis in cDC [11,12].
IkB kinase a (IKKa) has been shown to associate and activate
IRF-1 during TLR7/9 signaling in cDC [12] and acts specifically
via IRFs to induce the production of IFN. Given the importance of
TLRs in host defense against pathogens, dissection of TLR7/9
signaling pathways becomes an important research focus. How-
ever, the TLR7/9 signaling pathway leading to IKKa and IRF-1
activation in cDC has been relatively unexplored and it is
currently not known which other signaling molecules participate in
TLR7/9-signaling leading to IRF-1 activation and IFN-b
synthesis. Thus in this current study, we set out to determine the
upstream signaling molecules that might play a role in TLR7/9-
induced activation of IKKa and IRF-1 leading to IFN-b
production.
Bruton’s tyrosine kinase (BTK) is a member of the Tec family of
protein tyrosine kinases and has previously been shown to play
important roles in B cell development, activation and survival.
Mutations in BTK are known to lead to X-linked agammaglob-
ulinemia (XLA) in humans and X-linked immunodeficiency (xid) in
mice [13]. BTK has been shown to be activated by B cell antigen
receptor (BCR) [14], cytokine receptors [15,16], as well as TLR
[17,18,19,20] engagement. It is well documented that TLR-
induced NF-kB activation is defective in BTK-deficient cells
[21,22,23]. We and others also demonstrated that BTK played a
critical role in MyD88-dependent TLR-signaling of proinflamma-
tory cytokine production in B cells [17], macrophages [18,20] and
CDC [24,25]. In addition, we recently showed that BTK is
required to phosphorylate TLR3 for IFN-b production [26].
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However, it is unclear if BTK plays a role in TLR7/9-induction of
IFN-b synthesis in CDC.
In addition to BTK, it is conceivable that other signaling
molecules could contribute to TLR7/9-induced IFN-b produc-
tion. Various PKCs have been found to be important for TLR-
induced production of proinflammatory cytokines [27,28] and
PKCa has been shown to be involved in TLR3-induced IFN-b
synthesis [29]. Protein Kinase C (PKC) is a class of serine/
threonine kinase that is subdivided into three main groups, namely
conventional PKCs, novel PKCs, and atypical PKC [30,31].
Protein kinases D, consisting of PKD1 (also known as PKCm),
PKD2, and PKD3, are extended family members of PKC [32]. It
is also not clear currently whether PKC participates, and if so,
which PKC member is involved in TLR7/9-induced IFN-b
production in CDC. In this paper, we undertook to examine if




All experiments and procedures were performed in compliance
with Guidelines on the Care and Use of Animals for Scientific
Purposes of the National Advisory Committee for Laboratory
Animal Research (NACLAR) of Singapore. The protocol was
approved by the Institutional Animal Care and Use Committee of
the Biological Resource Center (BRC) of Agency for Science,
Technology and Research (A*STAR) (Authorized IACUC No
110611). Steps were taken to minimize animal suffering.
Mice
Wild type C57BL/6 mice were obtained from the BRC, and
btk2/2 mice were obtained from The Jackson Laboratory.
Cells and transfection
Conventional dendritic cells (CDC) were differentiated as
described [33,34]. Briefly, bone marrow (BM) cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mm l-
glutamine, 50 mm 2-mercaptoethanol, 10% heat-inactivated fetal
calf serum, and 1% supernatant of granulocyte-macrophage
colony-stimulating factor-transduced X-63 cells. After 6 to 7 days
of culture, CDC were purified using anti-CD11c monoclonal
antibody-coupled magnetic beads (Miltenyl Biotech). For PKCm
knock down studies, 5 mg of PKCm siRNA or scrambled siRNA
(Santa Cruz) were transfected into purified CDC (16106 cells per
reaction) using Amaxa Nucleofector device and reagents as per
manufacturer’s instructions (Amaxa). Transfected CDC were
maintained for an additional 24 h before stimulation.
Reagents
The following reagents were purchased and used in the study:
TLR7 agonist R848 and TLR9 ligand CpG-ODN 1668 (CpG)
(Invivogen); PKC inhibitors Go¨ 6976 and non-inhibitory analog
Go¨ 6983 (Calbiochem). Antibodies used for immunoblot analyses
were from Santa Cruz: anti-BTK, anti-IKKa/b, anti-PKCm, anti-
IRF-1, anti-HDAC-1, anti-b-actin, donkey anti-goat IgG-horse-
radish peroxidase, goat anti-rabbit IgG-horseradish peroxidase,
and goat anti-mouse IgG-horseradish peroxidase; from Cell
Signaling: anti-phospho-BTK (Tyr223), anti-phospho-PKCm
(Ser916) and anti-phospho-IKKa (Ser180)/IKKb (Ser181). The
anti-phosphotyrosine horseradish peroxidase-conjugated antibody
(4G10) was from Upstate Biotech.
Immunoprecipitations and western blot analyses
Cells were treated for various times as shown with the indicated
stimuli, followed by immunoprecipitations and western blot
analyses as described previously [17]. 10 million wild type and
btk2/2 CDC were plated onto 3cm dish, left untreated or
stimulated with R848 or CpG and then washed with cold PBS
and lysed on ice for 30 mins in 500 ml phospholysis buffer
containing 1% Nonidet P-40, 10 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 1 mM EDTA, 0.2 mM Na3VO4, and a cocktail of protease
inhibitors (Roche). Whole cell lysates were obtained after
centrifugation at 13,000 rpm for 10 mins at 4uC. For immuno-
precipitation studies, cell lysates were pre-cleared with Protein A/
G Plus-agarose in the presence of goat IgG (Santa Cruz) for 1 h at
4uC. 3 mg of anti-BTK antibody and 20 ml beads were added to
the pre-cleared lysate and rotated for 3 h at 4uC. Subsequently,
beads were washed 3 times with phospholysis buffer and boiled in
loading buffer for 10 mins. For Western blot analyses, whole cell
lysates or immunoprecipitated proteins were electrophoresed in
10% SDS-polyacrylamide gels and transferred onto immunoblot
polyvinylidene difluoride membranes (Millipore). The membranes
were then probed with antibodies of interest (1:1000) and
normalized for total protein or b-actin. To examine nuclear
translocation of IRF-1, nuclear proteins from untreated or
stimulated wild type and btk2/2 CDC were prepared using NE-
PER Nuclear and Cytoplasmic Extraction Reagents according to
manufacturer’s instruction (Pierce). Nuclear proteins were probed
with anti-IRF-1 and normalized with anti-HDAC-1 antibodies.
Measurement of IFN-b production by ELISA or
Quantitative RT-PCR
Cells were treated for 6 h with the indicated stimuli, and IFN-b
production was measured by ELISA as described [12]. Briefly,
untreated or CpG-stimulated wild type and btk2/2 CDC cells were
cultured in 24-well plates at 16106 cells/ml. At 6 h poststimula-
tion, supernatants were harvested and stored at -20uC or
immediately assayed for cytokine production. The concentrations
of IFN-b were determined using commercial ELISA kit (PBL
Interferon Source) according to manufacturer’s instructions. For
quantification of IFN-b mRNA synthesis, total RNA was extracted
from wild type and btk2/2 CDC at 2 h post-stimulation using
Trizol (Invitrogen), and cDNA was synthesized with Superscript II
reverse transcriptase as per manufacturer’s protocol (Invitrogen).
Quantitative PCR was performed on an Applied Biosystems 7500






0.1 million WT or btk2/2 cDC were plated on glass-bottomed
35 mm dish, stimulated for 1 h with R848 (1 mM) in the presence
or absence of Go¨ 6976 or Go¨ 6983 (30 min pre-treatment, 37uC)
and then fixed in 4% paraformaldehyde (5 min, RT), washed in
PBS, permeabilized with 1% Triton X-100 in PBS for 10 minutes
at RT and rinse well with PBS. The dish was then blocked with
3% BSA (1 h, RT). Cells were later incubated for 16 hrs at 4uC
with anti-IRF-1 antibody (1:50) in PBS containing 3% BSA. After
incubation with secondary anti-Rabbit IgG PE antibody (1:50,
1 h, RT), cells were washed and mounted with coverslips using
VECTASHIELD Mounting Medium with DAPI (Vector Labo-
ratories). Images of cells were taken and analyzed using an
BTK and PKCm in TLR7/9-Induced IFN-b Synthesis
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e105420
Olympus Fluoview Version 2.1 software using 100X objectives
with oil.
Statistics
Statistical analysis was performed using Student’s t test (Prism).
p values of ,0.05 were considered significant.
Results
BTK is phosphorylated upon TLR7/9 engagement in CDC
To determine if BTK is involved in TLR7/9 signaling, we
differentiated cDC from bone marrow (BM) precursors and
stimulated them with the TLR7 agonist R848 or the TLR9 ligand
CpG ODN-1668 (CpG) and examined if BTK is phosphorylated
upon TLR engagement. After treatment of wild type CDC with
R848 or CpG, total BTK was immunoprecipitated and probed for
tyrosine phosphorylation using the phospho-tyrosine specific
antibody 4G10. As shown in Fig. 1A, BTK was activated, as
indicated by its tyrosine phosphorylation status upon stimulation
of CDC with R848. Similarly, stimulation of CDC with CpG also
led to the phosphorylation of BTK (Fig. 1B). To confirm the
phosphorylation of BTK, the same cell lysates were also subjected
to immunoblot with anti-phospho-BTK (Y223) antibody. Consis-
tently we observed an increase in the amount of phosphorylated
BTK in cDC after treatment of these cells with either R848
(Fig. 1C) or CpG (Fig. 1D). Thus, these data indicated that BTK
was activated during TLR7/9 signaling in CDC. This result adds
onto our previous demonstration of a role for BTK in TLR9
signaling in B cells [17] and other cell types [18,20,35,36]. In
addition, our current finding also demonstrates that BTK is
activated upon TLR7 stimulation in CDC, which has not been
previously documented.
BTK is involved in IFN-b production following TLR7/9-
stimulation in CDC
Signaling through TLR7/9 leads to the secretion of IFN-a in
plasmacytoid dendritic cell (pDC) [3,10] and IFN-b in CDC [12].
Previously our laboratory has demonstrated that BTK played a
critical role in TLR9-induced production of proinflammatory
cytokines such as IL-6, IL-12 and TNF-a [17] in B cells. Here, we
asked if BTK participates in TLR7/9-induced production of IFN-
b in CDC. As shown in Fig. 2, the synthesis of IFN-b mRNA was
highly induced in wild type CDC when they were stimulated for
2 h with R848 (A) or CpG (B). By contrast, there was a significant
reduction of IFN-b mRNA induction in R848 or CpG-stimulated
btk2/2 CDC. This finding was further confirmed when we
measured secreted IFN-b protein level via ELISA from CpG
stimulated btk2/2 CDC (Fig. 2C). Hence, the data indicated that
BTK is important for TLR7/9-induced IFN-b production in
CDC.
Activation of IkB kinase a and IRF-1 is impaired in TLR7/9-
stimulated btk2/2 CDC
So far, not much is known of the TLR7/9 signaling pathway
that leads to IFN-b production in CDC. The only well-established
molecules in the activation process are IKKa that induces IRF-1
in CDC [12] and IRF-7 in pDC [9,10]. BTK had previously been
reported to be required for IkB kinase activation in B lymphocytes
[21] and IRF-3 induction in macrophages [26]. However, it is not
known whether BTK plays a role in IKKa and IRF-1 activation in
CDC.
To investigate whether BTK is involved in the TLR7/9
signaling pathway leading to IKKa induction in CDC, we
examined the activation of IKKa/b using an anti-phospho-
IKKa/b specific antibody. As shown in Fig. 3A, TLR7-induced
activation of IKKa/b was markedly attenuated in btk2/2 CDC as
compared with wild type controls when these cells were treated
with R848 agonists. The reduced phosphorylation pattern of
IKKa/b was observed across the various time points examined.
Similar defects were also observed when btk2/2 CDC were
stimulated with the TLR9-ligand, CpG (Fig. 3B). Hence, BTK is
critical for the optimal activation of IKKa/b during TLR7/9
engagement.
Figure 1. Bruton’s tyrosine kinase is phosphorylated upon TLR7/9 stimulation in cDC. Purified wild type CDC (10 million cells per 3 cm
dish) were untreated or stimulated for 5 mins with either (A) TLR7 agonist (R848, 1 mM) or (B) TLR9 ligand (CpG ODN-1668, 0.1 mM). Cells were then
lysed in 500 ml lysis buffer for 30 min on ice and BTK was immunoprecipitated and probed with anti-phospho-tyrosine antibody (pY, 4G10) and
reprobed with anti-BTK antibodies. Total lysates after R848 (C) or CpG (D) treatment were also immunoblotted with anti-phospho-BTK (Y223) and re-
probed with BTK antibodies for equal loading of BTK. Results shown are representative of three independent experiments. The intensities of the
bands were quantified by ImageJ and the ratio of 4G10 or phopspho-BTK (Y223) over BTK in each sample was then calculated and presented. *p,
0.05, **p,0.005 (Student’s t test), compared to untreated cells.
doi:10.1371/journal.pone.0105420.g001
BTK and PKCm in TLR7/9-Induced IFN-b Synthesis
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e105420
Induction of IKKa in TLR7/9-activated CDC is known to lead
to the phosphorylation and nuclear translocation of IRF
transcription factors that drive the synthesis of type I IFNs
[10,12]. IFN-b gene expression is regulated by different IRF
family members in different cell types and upon different stimuli
[9,37]. CDC utilizes IRF-1 for TLR9-induced IFN-b production
[11,12,38]. To determine if the activation of IRF-1 was affected in
TLR7/9-stimulated btk2/2 CDC, we examined the nuclear
translocation of IRF-1 in these cells. As shown in Fig. 3C, the
engagement of TLR7 by R848 led to the activation and nuclear
translocation of IRF-1 in wild type CDC. By contrast, the
activation of IRF-1 was largely compromised in R848-treated
btk2/2 CDC. Similar finding was also observed for CpG-stimulated
btk2/2 CDC (Fig. 3D). Furthermore, when confocal imaging
microscopy was used to analyze IRF-1 localization, we observed
increased translocation of IRF-1 into the nucleus of cells after
R848 stimulation. By contrast, IRF-1 translocation to the nucleus
was not evident in btk2/2 CDC (Fig. 3E). Collectively, our results
indicated that the signal transduced by BTK is required to activate
IKKa/b and subsequently, IRF-1 in TLR7/9-stimulated CDC.
PKCm phosphorylation is impaired in TLR7/9-stimulated
btk2/2 CDC
BTK is known to interact with a number of signaling molecules
in various immune and cytokine receptor signaling [39]. One of
these molecules is Protein Kinase C (PKC) [40]. Various PKC
isoforms are known to be involved in the signaling cascade leading
to NF-kB activation [41,42,43,44]. For example, PKCb is critical
for B cell-receptor induced IKK activation [43]. On the other
hand, PKCa has been shown to be important for MyD88-
dependent TLR signaling leading to proinflammatory cytokine
production in DC [27] and for TLR3-induced IRF-3 activation
and IFN-b synthesis [29]. PKCm (PKD1) has also been shown to
be important for TLR9 [45] and other MyD88-dependent TLR
signaling of pro-inflammatory cytokine production in CDC [46].
However, in all these studies, it is not clear if PKCm is activated
during TLR7/9 signaling and if it played a role in TLR7/9-
induced IFN-b production and if BTK has a role in the activation
of PKCm.
First, to determine if any PKC would be involved and acts
downstream of BTK in TLR7/9-induced activation of IFN-b
production, we examined if the activation of any of the PKC
isoforms would be compromised in R848 or CpG-stimulated btk2/2
CDC. Surprisingly, PKCa/b phosphorylation was found to be
comparable between TLR7-stimulated wild type and btk2/2 CDC
(Fig. 4A). However as shown in Fig. 4B & C, the phosphorylation of
PKCm was up-regulated in WT cDC treated with R848 or CpG. By
contrast, the activation of PKCm was severely attenuated across all
time points tested in R848-stimulated btk2/2 CDC compared with
similarly-treated wild type controls. The activation of PKCm was
also found to be defective in TLR9-stimulated btk2/2 CDC
(Fig. 4C). Thus, PKCm was activated by TLR7/9 engagement in
cDC and the absence of BTK in cDC specifically impaired the
activation of PKCm. These data suggest that PKCm is involved and
acts downstream of BTK in TLR7/9-signaling in CDC.
Reduced expression of PKCm impairs TLR7/9-induced IFN-
b synthesis
Our data above suggested that PKCm is activated by TLR7/9
stimulation and its activation is impaired in the absence of BTK.
Although PKCm has been implicated in TLR9 signaling of
proinflammatory cytokine production [45], it has not been shown
whether PKCm is involved in TLR7/9-induced IFN-b production.
To address this, we inhibit PKCm activity using a specific chemical
inhibitor Go¨ 6976 [47]. We pre-treated CDC with this inhibitor
and subsequently stimulated the cells with either R848 or CpG
and examined their induction of IFN-b mRNA. As shown in
Fig. 5A & B, Go¨ 6976-treated and hence, PKCm-inhibited CDC
Figure 2. TLR7/9-induced IFN-b production is defective in btk2/2
CDC. Purified wild type or btk2/2 CDC were untreated or stimulated for
2 h with either (A) R848 (1 mM) or (B) CpG (0.1 mM). IFN-b mRNA was
quantified by qRT-PCR with primers as listed in materials and methods.
IFN-b mRNA expression was normalized to b-actin, and the value from
un-stimulated cells was set as 1. Numbers represent mean6SEM of
three experiments. **, p , 0.005; *, p , 0.05 (Student’s t test). (C) IFN-b
protein level in the supernatants of untreated (media) or CpG (0.1 mM,
6 h) stimulated CDC were also measured via ELISA using known
standards. *, p , 0.05 (Student’s t test). Error bars show the standard
error calculated from three biological replicates.
doi:10.1371/journal.pone.0105420.g002
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failed to induce IFN-b mRNA synthesis upon TLR7/9 stimula-
tion. By contrast, non-treated or CDC treated with Go¨ 6983, a
non-inhibiting analog of Go¨ 6976, were able to robustly synthesize
IFN-b when they were stimulated with R848 or CpG. These data
suggest that PKCm played a role in TLR7/9-induced IFN-b
production.
To determine if PKCm acts in the same pathway as IKKa and
IRF-1 in inducing IFN-b production, we examined the activation
of IKKa/b and IRF-1 in R848 or CpG-stimulated CDC with or
without Go¨ 6976 or Go¨ 6983 pre-treatment. As shown in Fig. 5C,
stimulation of CDC with R848 induces IKKa/b and IRF-1
activation, as assessed by the phosphorylation of IKKa/b and
nuclear localization of IRF-1. However, the extent of IKKa/b
phosphorylation and IRF-1 nuclear localization were very much
reduced in Go¨ 6976-treated and R848-stimulated cells. By
contrast, the activation of IKKa and IRF-1 remain intact in Go¨
6983-treated R848-stimulated cells. The same observations were
also found to hold true for Go¨ 6976 or Go¨ 6983 pre-treated CDC
that were also stimulated with GpG (Fig. 5D). Furthermore, when
confocal imaging microscopy was used to check the cellular
Figure 3. Impaired activation of IKKa/b and IRF-1 in TLR7/9-stimulated btk2/2 CDC. Wild type and btk2/2 CDC were stimulated with 1 mM
R848 (A) or 0.1 mM CpG (B) for various times as indicated and IKKa/b activation was examined via immunoblot analyses using anti-phospho-IKKa
(Ser180)/IKKb (Ser181) antibody. The anti-IKKa/b blot was included as loading control. Densitometric ratios of phospho-IKKa (Ser180)/IKKb (Ser181) over
IKKa/b are graphed and shown in the lower panels of A and B. *p,0.05, **p,0.005 (Student’s t test). (C & D) Nuclear translocation of IRF-1 in cDC that
were stimulated for 1 h with R848- (C) or CpG- (D). Nuclear extracts were obtained from non-treated or 1 h stimulated wild type and btk2/2 CDC and
examined for the presence of IRF-1 via western blot analyses. The anti-HDAC1 blot was included as loading control. The ratio of densitometric values
of IRF-1 over HDAC1 is shown in lower panels of C and D. Numbers represent mean6SEM of three experiments. **p,0.005 (Student’s t test). (E)
Immunofluorescence confocal studies of IRF-1 localization in wild type and btk2/2 cDC that were untreated or stimulated for 1 h with 1 mM R848.
Bar = 10 mM. Results shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0105420.g003
Figure 4. Defective PKCm activation in TLR7/9-stimulated btk2/2 cDC. Wild type and btk2/2 cDC were stimulated with R848 (A & B, 1 mM) or
CpG (C, 0.1 mM) for various times as indicated and the activation of PKCa/b (A) or PKCm (B & C) was examined by immunoblotting with anti-phospho-
PKCa/b (Thr638/641) or anti-phospho-PKCm (Ser916) antibodies. Immunoblot membranes were re-probed with anti-PKCa/b or anti-PKCm antibodies to
check for equal loading of lysates. The ratios of the intensity of phospho-PKCa/b (Thr638/641) over PKCa/b (A) and phospho-PKCm (Ser916) over PKCm (B
& C) are shown on the right. Numbers represent mean6SEM of three experiments. *p,0.05 (Student’s t test). Gels shown are representative of three
independent experiments.
doi:10.1371/journal.pone.0105420.g004
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Figure 5. Chemical inhibition of PKCm activity compromises TLR7/9-inducd IKKa/b and IRF-1 activation and IFN-b synthesis in cDC.
Wild type CDC were non-treated or pretreated for 30 mins with PKC inhibitors Go¨ 6976 (0.1 mM) or the non-inhibitory analog Go¨ 6983 (1 mM),
followed by stimulation with R848 (1 mM) (A) or CpG (0.1 mM) (B) for 2 h and IFN-b mRNA expression was measured. Data were analyzed as in Fig. 2A.
(C & D), Western blot analyses of IKKa/b and IRF-1 activation in PKCm-inhibited TLR7/9-stimulated CDC. Wild type CDC were non-treated or pretreated
for 30 mins with PKC inhibitors Go¨ 6976 (0.1 mM) or the non-inhibitory analog Go¨ 6983 (1 mM), followed by stimulation with R848 (1 mM) (C) or CpG
(0.1 mM) (D) for 1 h. Activation of IKKa/b was examined using anti-phospho-IKKa (Ser180)/IKKb (Ser181) antibody. The anti-IKKa/b blot served as
loading control. Determination of IRF-1 activation was performed using anti-IRF-1 antibodies after nuclear extraction. The anti-HDAC1 immunoblots
served as loading control. The ratios of the intensities of phospho-IKKa (Ser180)/IKKb (Ser181) over IKKa/b and IRF-1 over HDAC1 are shown below the
gels. **p,0.005, ***p,0.001 (Student’s t test), compared to R848- or CpG-treated cells without PKCm inhibition. (E) Confocal immunofluorescence
study of IRF-1 localization in PKCm-inhibited and R848-stimulated cDC. Wild type cDC were untreated or pre-treated for 30 mins with Go¨ 6976
(0.1 mM) or 6983 (1 mM), followed by stimulation with 1 mM R848 for 1 h. Bar = 10 mM. Results shown are representative of at least three independent
experiments.
doi:10.1371/journal.pone.0105420.g005
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localization of IRF-1, we observed increased IRF-1 in the nucleus
after R848 stimulation. However, nuclear IRF-1 was very much
reduced in Go¨ 6976 pre-treated CDC (Fig. 5E). Thus, inhibition of
PKCm activity perturbs IKKa/b and IRF-1 activation and impairs
IFN-b synthesis in TLR7/9-stimulated CDC.
To further confirm that PKCm is critical for TLR7/9-induced
IFN-b production, we knockdown PKCm expression in primary
CDC using siRNA technology. Purified CDC were harvested on
day 6 of culture and transfected with either scrambled siRNA (Scr)
or PKCm-specific siRNA (si-m). Cells were allowed to grow for an
additional 24 h before stimulation with CpG. As shown in Fig. 6A
& B, PKCm expression could indeed be reduced by PKCm-specific
siRNA compared to scrambled siRNA treatment. As a control, we
showed that the knockdown of PKCm expression did not affect the
expression of IKKa/b or b-actin. When PKCm expression was
successfully knocked-down, the activation of IKKa/b was
attenuated in CpG-stimulated cDC. Consistent with the reduced
activation of IKKa/b in the CpG-stimulated and si-PKCm-
transfected CDC, the synthesis of IFN-b mRNA was also defective
(Fig. 6C).
Taken together, our data indicated that the reduction of PKCm
activity or expression perturbs the activation of IKKa/b and
nuclear translocation of IRF-1 which in turn lead to impaired
IFN-b production in TLR7/9-stimulated CDC.
Discussion
The signaling pathway leading to IFN-b synthesis upon TLR7/
9 stimulation in cDC has not been well characterized. Although it
is well established that TLR3 and TLR4 could induce type 1
interferon production in cDC and macrophages through the
activation of IRF-3 [48,49,50], most studies of TLR7/9-induced
production of type 1 IFN had centered on the activation of the
different IRFs in different cell types. For example, IRF-1 and IRF-
7 have been shown to be important for IFN production in cDC
and pDC, respectively [8,11,38]. In recent years, Kaisho and
colleagues had expanded on these studies by showing that IKKa
played an important role in TLR7/9 signaling of IFNa production
in pDC [10] and IFN-b production in cDC [12]. In this paper, we
further extended these analyses and sought to delineate the
signaling partners that acts upstream of IKKa and IRF in the
induction of IFN-b synthesis triggered by TLR7/9 engagement in
cDC.
It was previously demonstrated that BTK played a critical role
in MyD88/TLR-dependent proinflammatory cytokine production
in various cell types [17,18,24]. However, a role for BTK in
TLR7/9 signaling of IFN-b production in cDC has not been
explored. Our current study shows that BTK is indispensable for
IFN-b production in TLR7/9 activated CDC. More importantly,
our data indicate that BTK acts upstream of IKKa/b and IRF-1
in the TLR7/9 signaling pathway leading to IFN-b production in
cDC.
Other than BTK, our current work also establishes a role for
PKCm in the induction of IFN-b production by TLR7/9.
Although studies have implicated PKCa and PKCm in TLR-
induced proinflammatory cytokine production [27,45,46] and
PKCa in TLR3-induced IFN-b production via IRF-3 [29], it is
not known if there is a role for any PKC in the induction of IFN
synthesis through TLR7/9 and if so, which PKC isoform would be
involved in this process. Our data demonstrate that PKCm plays
an important role in TLR7/9-signaling of IFN-b production in
cDC and that it signals upstream of IKKa/b and IRF-1
activation. In addition, we identified BTK to be essential for
PKCm activation as its deficiency leads to defective PKCm
phosphorylation.
Although cDC possess other Tec family kinase and PKC
isoforms, we found BTK and PKCm to be non-redundant in
TLR7/9 activation of IKKa/b and IRF-1 for the induction of
IFN-b synthesis. Taken together, our study delineates a BTK-
PKCm-IKKa/b-IRF-1 signaling axis downstream of TLR7/9-
signaling that is critical for the induction of IFN-b synthesis in
cDC. Future work could be pursued to determine additional
binding partners or signaling molecules in TLR7/9-induced IFN-
b pathway in CDC.
Figure 6. siRNA-mediated knockdown of PKCm attenuated IKKa/b activation and IFN-b synthesis in CpG-stimulated CDC. PKCm siRNA
(si-m) or scrambled siRNA (Scr) were transfected into wild type CDC for 24 h prior to the stimulation of cells with CpG for 1 h. (A) Expression of PKCm
and activation of IKKa were examined via western blot analyses using anti-PKCm and anti-phospho-IKKa (Ser180)/IKKb (Ser181) antibodies, respectively.
The anti- IKKa/b and anti-b-actin blots served as loading control. Data shown are representative of 3 independent experiments. The intensity ratio of
phospho-IKKa (Ser180)/IKKb (Ser181) over IKKa/b is shown below the gels. *p,0.05 (Student’s t test), compared to the second lane of CpG-treated cells
transfected with scrambled siRNA. (B) PKCm expression level normalized to b-actin in scramble or PKCm siRNA transfected cDC. % PKCm level was
calculated with respect to scramble-transfected cells. (C) qRT-PCR analysis of IFN-b mRNA expression in CpG-stimulated cells with or without PKCm-
kockdown. Data were analyzed as in Fig. 2A. Numbers represent mean6SEM of three experiments. *p,0.05 (Student’s t test).
doi:10.1371/journal.pone.0105420.g006
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